Sign In  |  Register  

DOI: 10.1208/s12249-011-9693-zPages: 1293-1301

Sustained-Release Delivery of Octreotide from Biodegradable Polymeric Microspheres

1. University of Kentucky College of Pharmacy, Department of Pharmaceutical Sciences-Drug Development Division

2. Gyeongsang National University (GNU), College of Pharmacy

3. Oakwood Laboratories

4. Cardinal Health, Product Development

Correspondence to:
Heidi M. Mansour
Tel: +1-859-2571571
Email: heidi.mansour@uky.edu

Close

Abstract

The study reports on the drug release behavior of a potent synthetic somatostatin analogue, octreotide acetate, from biocompatible and biodegradable microspheres composed of poly-lactic-co-glycolic acid (PLGA) following a single intramuscular depot injection. The serum octreotide levels of three Oakwood Laboratories formulations and one Sandostatin LAR® formulation were compared. Three formulations of octreotide acetate-loaded PLGA microspheres were prepared by a solvent extraction and evaporation procedure using PLGA polymers with different molecular weights. The in vivo drug release study was conducted in male Sprague–Dawley rats. Blood samples were taken at predetermined time points for up to 70 days. Drug serum concentrations were quantified using a radioimmunoassay procedure consisting of radiolabeled octreotide. The three octreotide PLGA microsphere formulations and Sandostatin LAR® all showed a two-phase drug release profile (i.e., bimodal). The peak serum drug concentration of octreotide was reached in 30 min for all formulations followed by a decline after 6 h. Following this initial burst and decline, a second-release phase occurred after 3 days. This second-release phase exhibited sustained-release behavior, as the drug serum levels were discernible between days 7 and 42. Using pharmacokinetic computer simulations, it was estimated that the steady-state octreotide serum drug levels would be predicted to fall in the range of 40–130 pg/10 μL and 20–100 pg/10 μL following repeat dosing of the Oakwood formulations and Sandostatin LAR® every 28 days and every 42 days at a dose of 3 mg/rat, respectively.

This article is freely available, click here to access the full text/PDF

2069 Views

  • Accepted: Sep 12, 2011
  • Online: Sep 27, 2011

Article Tools

aaps journal